查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1890730

前列腺癌治疗市场规模、占有率、成长及全球产业分析：依类型、应用和地区划分的洞察与预测（2024-2032 年）

Prostate Cancer Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 请询问到货日

价格

前列腺癌治疗市场成长驱动因素

随着前列腺癌发病率的持续上升以及先进治疗方案的日益普及，全球前列腺癌治疗市场正在快速扩张。根据最新的产业评估，该市场在 2024 年的价值为 198.1 亿美元，预计到 2025 年将达到 251.2 亿美元。预计到 2032 年，该市场将飙升至 1,019.8 亿美元，在预测期内实现 22.16% 的强劲复合年增长率 (CAGR)。这一快速成长反映了标靶治疗、放射性药物、免疫疗法和新一代雄性激素受体抑制剂在全球的加速应用。

市场概况及区域领先地位

2024年，北美以50.98%的市场占有率引领全球前列腺癌市场，这主要得益于其高发病率、完善的医疗基础设施、早期治疗的普及以及创新疗法的广泛应用。美国仍然是规模最大、最具影响力的市场，这主要归功于前列腺癌发病率的上升、有利的医疗保险政策以及众多製药公司不断推出突破性疗法。

根据美国癌症协会统计，摄护腺癌主要影响老年男性，十分之六的病例发生在65岁及以上的人。确诊时的中位年龄约为67岁，随着全球老年人口的增长，治疗需求呈指数级增长。诸如一年一度的 "Movember" （鬍鬚月）活动等提高公众意识的活动，进一步促进了早期诊断和及时治疗。

市场成长驱动因素

全球前列腺癌发生率的上升是主要的成长因素。根据 GLOBOCAN 2022 的数据，全球新增摄护腺癌病例约 147 万例，摄护腺癌是全球第四大常见癌症。筛检率的提高、公众健康意识的增强以及诊断技术的进步，都促成了患者群体的成长。

技术进步也发挥关键作用。包括辉瑞、安斯泰来、强生、赛诺菲、阿斯特捷利康和艾伯维在内的主要製药公司，持续投资下一代疗法、联合疗法和个人化医疗。 PARP 抑制剂、雄性激素受体抑制剂和放射性配体疗法的研发正在重塑治疗指南，并有助于提高存活率。

市场限制因子

儘管成长前景强劲，但市场仍面临挑战。由于雄性激素受体突变导致的雄性激素剥夺疗法抗药性仍然是一个主要障碍，通常会导致去势抵抗性前列腺癌 (CRPC)。此外，荷尔蒙疗法和化疗常见的副作用，例如性慾减退、潮热、骨密度下降、疲劳和体重增加，会阻碍患者的依从性并影响治疗的连续性。

先进疗法的高昂费用也限制了其应用，尤其是在报销有限的中低收入地区。复杂的治疗方案和长期依从性要求也增加了整体医疗保健成本。

新兴市场的机会

研发活动正在加速，尤其是在转移性去势抵抗性前列腺癌 (mCRPC) 的联合治疗领域。 PARP 抑制剂与荷尔蒙疗法联合使用已显示出更高的疗效，并正在获得监管部门的批准。 2024年11月，拜耳的NUBEQA获得FDA批准，可作为ADT联合疗法用于转移性激素敏感性前列腺癌（mHSPC），这预示着联合疗法的应用前景将更加广阔。

针对包括BRCA1和BRCA2在内的基因突变的创新疗法正日益受到关注。例如，强生公司的AKEEGA于2023年获准用于治疗BRCA突变型转移性去势抵抗性摄护腺癌（mCRPC），这反映了精准癌症治疗日益受到重视。

细分市场洞察

雄性激素受体抑制剂（ARI）将在2024年占市场主导地位，市占率高达73.1%，这主要得益于其作为晚期前列腺癌一线治疗药物的日益普及。

由于患者强烈偏好，口服给药途径将引领市场，预计到 2025 年将占 86.7% 的市场占有率。

依治疗类型划分，激素疗法仍将占主导地位，因为它能够抑制雄激素依赖性肿瘤的生长。

依疾病状态划分，转移性去势抵抗性前列腺癌 (mCRPC) 占最大占有率，预计到 2025 年将占 83.7% 的市场占有率，这主要归功于其高临床需求以及靶向疗法频繁获得监管部门批准。

区域展望

  • 北美：市场规模最大，预计到 2025 年将达到 123.2 亿美元。
  • 欧洲：受益于强效药物的供应和临床进展，预计到 2025 年将达到 58.9 亿美元。
  • 亚太地区：受癌症意识提高和肿瘤治疗覆盖范围扩大的推动，预计到 2025 年将达到 44.8 亿美元。
  • 拉丁美洲和中东：由于公众意识提高和监管环境改善，预计将保持稳定成长。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：主要发现

  • 2024年主要国家及地区摄护腺癌盛行率
  • 主要公司产品线分析
  • 替代疗法概述
  • 市场主要新创企业
  • 主要公司新产品发布
  • 主要产业趋势（併购、合作等）
  • 新冠疫情的影响市场

第五章 全球前列腺癌治疗市场分析、洞察与预测（2019-2032）

  • 市场分析、洞察与预测 - 依药物类别划分
    • 雄性激素受体抑制剂
    • 微管抑制剂
    • 促性腺激素释放激素 (GnRH) 激动剂
    • 促性腺激素释放激素 (GnRH) 受体拮抗剂
    • 其他
  • 市场分析、洞察与预测 - 依给药途径划分
    • 口服
    • 肠外给药
  • 市场分析、洞察与预测 - 依疗法划分
    • 化疗
    • 荷尔蒙疗法
    • 标靶治疗治疗
    • 免疫疗法
  • 市场分析、洞察与预测 - 依疾病类型划分
    • 转移性去势抵抗性摄护腺癌
    • 非转移性去势抵抗性摄护腺癌
  • 市场分析、洞察与预测 - 依分销管道划分
    • 医院药房
    • 药局和零售药房
    • 线上药房
  • 市场分析、洞察与预测 - 依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美前列腺癌治疗市场分析、洞察与预测，2019-2032

  • 依国家/地区
    • 美国
    • 加拿大

第七章：欧洲前列腺癌药物市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚半岛
    • 欧洲其他地区

第八章：亚太地区前列腺癌药物市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 东南亚
    • 其他地区亚太地区

第九章 拉丁美洲前列腺癌治疗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章 中东与非洲前列腺癌治疗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 海湾合作委员会
    • 南非
    • 中东和非洲其他地区

第十一章 竞争分析

  • 全球市占率分析（2024）
  • 公司公司简介
    • 安斯泰来药厂
    • 辉瑞公司
    • 强生服务公司
    • 赛诺菲
    • 费林製药公司
    • 住友製药株式会社（Myovant Sciences GmbH）
    • 艾伯维公司
    • 阿斯特捷利康
    • 托玛公司
    • Dendreon Pharmaceuticals LLC
    • 拜耳股份公司
Product Code: FBI112008

Growth Factors of prostate cancer therapeutics Market

The global prostate cancer therapeutics market is expanding rapidly as the prevalence of prostate cancer continues to rise and advanced treatment options become more accessible. According to the latest industry assessment, the market was valued at USD 19.81 billion in 2024, is projected to reach USD 25.12 billion in 2025, and is expected to surge to USD 101.98 billion by 2032, registering a robust CAGR of 22.16% during the forecast period. The sharp increase reflects accelerated adoption of targeted therapies, radiopharmaceuticals, immunotherapies, and next-generation androgen receptor inhibitors worldwide.

Market Overview and Regional Leadership

In 2024, North America dominated the global market with a 50.98% share, driven by a high prostate cancer burden, strong healthcare infrastructure, early therapy adoption, and extensive availability of innovative treatment options. The U.S. remains the largest and most influential market owing to the rising incidence of prostate cancer, supportive reimbursement policies, and a strong presence of pharmaceutical companies introducing breakthrough therapies.

Prostate cancer predominantly affects older men, with 6 in 10 diagnoses occurring in individuals aged 65 and above, according to the American Cancer Society. The median age of diagnosis is around 67, and as the global geriatric population grows, treatment demand is increasing sharply. Rising awareness initiatives such as the annual Movember campaign further support early diagnosis and timely therapeutic intervention.

Market Growth Drivers

The rising global prevalence of prostate cancer is a major growth catalyst. GLOBOCAN 2022 reported approximately 1.47 million new cases, ranking prostate cancer as the fourth most prevalent cancer worldwide. Increased screening rates, public health awareness, and improved diagnostic technologies contribute to the expanding patient pool.

Technological advancements also play a key role. Pharmaceutical leaders including Pfizer, Astellas, Johnson & Johnson, Sanofi, AstraZeneca, and AbbVie are continually investing in next-generation therapies, combination regimens, and personalized medicine. The development of PARP inhibitors, androgen receptor inhibitors, and radioligand therapies is reshaping treatment guidelines and improving survival outcomes.

Market Restraints

Despite strong growth prospects, the market faces challenges. Resistance to androgen deprivation therapy-caused by androgen receptor mutations-remains a significant barrier, often leading to Castration-Resistant Prostate Cancer (CRPC). Additionally, common side effects of hormonal and chemotherapies, such as decreased libido, hot flashes, reduced bone density, fatigue, and weight gain, hinder patient adherence and impact treatment continuity.

The high cost of advanced therapies further restricts adoption, particularly in low- and middle-income regions where reimbursement systems are limited. Complex treatment regimens and long-term medication requirements also elevate overall healthcare expenditures.

Emerging Market Opportunities

Research and development activities are accelerating, particularly in the field of combination therapies for managing metastatic castration-resistant prostate cancer (mCRPC). PARP inhibitors combined with hormonal therapies are showing enhanced efficacy and gaining regulatory approval. In November 2024, Bayer's NUBEQA received FDA acceptance for use with ADT in metastatic hormone-sensitive prostate cancer (mHSPC), signaling expanding opportunities for combination regimens.

Innovative therapies targeting genetic mutations, including BRCA1 and BRCA2, are gaining traction. For example, Johnson & Johnson's AKEEGA, approved in 2023 for BRCA-mutated mCRPC, reflects the growing emphasis on precision oncology.

Segmental Insights

Androgen receptor inhibitors dominated the market in 2024 with a 73.1% share, supported by rising adoption for first-line treatment in advanced prostate cancer.

The oral route of administration led the market with strong patient preference and is set to capture 86.7% of the market in 2025.

By therapy, hormonal therapy remains the leading segment due to its effectiveness in controlling androgen-dependent tumor growth.

By disease state, mCRPC accounted for the dominant share, expected to capture 83.7% of the market in 2025, due to high clinical need and frequent regulatory approvals for targeted therapies.

Regional Outlook

  • North America: Strongest market; expected to reach USD 12.32 billion in 2025.
  • Europe: Projected to reach USD 5.89 billion in 2025, supported by strong drug availability and clinical advancements.
  • Asia Pacific: Expected to reach USD 4.48 billion in 2025, driven by increased cancer awareness and expanding access to oncology treatments.
  • Latin America & Middle East: Steady growth with increased awareness and improving regulatory landscapes.

Conclusion

With its market size rising from USD 19.81 billion in 2024 to a projected USD 101.98 billion by 2032, the prostate cancer therapeutics market is undergoing transformative expansion. The rapid integration of precision medicines, combination therapies, and immunotherapies-coupled with increasing disease prevalence-will continue to drive substantial growth through 2032.

Segmentation By Drug Class

  • Androgen Receptor Inhibitors
  • Microtubule Inhibitors
  • Gonadotropin Releasing Hormone (GnRH) Agonist
  • Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Therapy

  • Chemotherapy
  • Hormonal Therapy
  • Targeted therapy
  • Immunotherapy

By Disease State

  • Metastatic Castration-Resistant Prostate Cancer
  • Non-Metastatic Castration-Resistant Prostate Cancer

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (By Drug Class, Route of Administration, Therapy Type, Disease State, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Drug Class, Route of Administration, Therapy Type, Disease State, Distribution Channel, and Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific (By Drug Class, Route of Administration, Therapy Type, Disease State, Distribution Channel, and Country/Sub-Region)
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, Route of Administration, Therapy Type, Disease State, Distribution Channel, and Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, Route of Administration, Therapy Type, Disease State, Distribution Channel, and Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Prostate Cancer - by Key Countries/Regions, 2024
  • 4.2. Pipeline Analysis, by Key Players
  • 4.3. Overview of Alternative Therapies
  • 4.4. Key Start-ups in the Market
  • 4.5. New Product Launches, by Key Players
  • 4.6. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.7. Impact of COVID-19 on the Market

5. Global Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Androgen Receptor Inhibitors
    • 5.1.2. Microtubule Inhibitors
    • 5.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 5.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
  • 5.3. Market Analysis, Insights and Forecast - By Therapy
    • 5.3.1. Chemotherapy
    • 5.3.2. Hormonal Therapy
    • 5.3.3. Targeted therapy
    • 5.3.4. Immunotherapy
  • 5.4. Market Analysis, Insights and Forecast - By Disease State
    • 5.4.1. Metastatic Castration-Resistant Prostate Cancer
    • 5.4.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.5.1. Hospital Pharmacies
    • 5.5.2. Drug Stores & Retail Pharmacies
    • 5.5.3. Online Pharmacies
  • 5.6. Market Analysis, Insights and Forecast - Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Androgen Receptor Inhibitors
    • 6.1.2. Microtubule Inhibitors
    • 6.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 6.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
  • 6.3. Market Analysis, Insights and Forecast - By Therapy
    • 6.3.1. Chemotherapy
    • 6.3.2. Hormonal Therapy
    • 6.3.3. Targeted therapy
    • 6.3.4. Immunotherapy
  • 6.4. Market Analysis, Insights and Forecast - By Disease State
    • 6.4.1. Metastatic Castration-Resistant Prostate Cancer
    • 6.4.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.5.1. Hospital Pharmacies
    • 6.5.2. Drug Stores & Retail Pharmacies
    • 6.5.3. Online Pharmacies
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Androgen Receptor Inhibitors
    • 7.1.2. Microtubule Inhibitors
    • 7.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 7.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
  • 7.3. Market Analysis, Insights and Forecast - By Therapy
    • 7.3.1. Chemotherapy
    • 7.3.2. Hormonal Therapy
    • 7.3.3. Targeted therapy
    • 7.3.4. Immunotherapy
  • 7.4. Market Analysis, Insights and Forecast - By Disease State
    • 7.4.1. Metastatic Castration-Resistant Prostate Cancer
    • 7.4.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.5.1. Hospital Pharmacies
    • 7.5.2. Drug Stores & Retail Pharmacies
    • 7.5.3. Online Pharmacies
  • 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.6.1. Germany
    • 7.6.2. U.K.
    • 7.6.3. France
    • 7.6.4. Italy
    • 7.6.5. Spain
    • 7.6.6. Scandinavia
    • 7.6.7. Rest of Europe

8. Asia Pacific Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Androgen Receptor Inhibitors
    • 8.1.2. Microtubule Inhibitors
    • 8.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 8.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
  • 8.3. Market Analysis, Insights and Forecast - By Therapy
    • 8.3.1. Chemotherapy
    • 8.3.2. Hormonal Therapy
    • 8.3.3. Targeted therapy
    • 8.3.4. Immunotherapy
  • 8.4. Market Analysis, Insights and Forecast - By Disease State
    • 8.4.1. Metastatic Castration-Resistant Prostate Cancer
    • 8.4.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.5.1. Hospital Pharmacies
    • 8.5.2. Drug Stores & Retail Pharmacies
    • 8.5.3. Online Pharmacies
  • 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.6.1. China
    • 8.6.2. Japan
    • 8.6.3. India
    • 8.6.4. Australia
    • 8.6.5. Southeast Asia
    • 8.6.6. Rest of Asia Pacific

9. Latin America Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Androgen Receptor Inhibitors
    • 9.1.2. Microtubule Inhibitors
    • 9.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 9.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Parenteral
  • 9.3. Market Analysis, Insights and Forecast - By Therapy
    • 9.3.1. Chemotherapy
    • 9.3.2. Hormonal Therapy
    • 9.3.3. Targeted therapy
    • 9.3.4. Immunotherapy
  • 9.4. Market Analysis, Insights and Forecast - By Disease State
    • 9.4.1. Metastatic Castration-Resistant Prostate Cancer
    • 9.4.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.5.1. Hospital Pharmacies
    • 9.5.2. Drug Stores & Retail Pharmacies
    • 9.5.3. Online Pharmacies
  • 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Androgen Receptor Inhibitors
    • 10.1.2. Microtubule Inhibitors
    • 10.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 10.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Parenteral
  • 10.3. Market Analysis, Insights and Forecast - By Therapy
    • 10.3.1. Chemotherapy
    • 10.3.2. Hormonal Therapy
    • 10.3.3. Targeted therapy
    • 10.3.4. Immunotherapy
  • 10.4. Market Analysis, Insights and Forecast - By Disease State
    • 10.4.1. Metastatic Castration-Resistant Prostate Cancer
    • 10.4.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.5.1. Hospital Pharmacies
    • 10.5.2. Drug Stores & Retail Pharmacies
    • 10.5.3. Online Pharmacies
  • 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.6.1. GCC
    • 10.6.2. South Africa
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. Astellas Pharma Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Pfizer Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Johnson & Johnson Services, Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Sanofi
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Ferring Pharmaceuticals Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Sumitomo Pharma Co., Ltd. (Myovant Sciences GmbH)
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. AbbVie Inc.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. AstraZeneca
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Tolmar, Inc.
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Dendreon Pharmaceuticals LLC.
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)
    • 11.2.11. Bayer AG
      • 11.2.11.1. Overview
      • 11.2.11.2. Products
      • 11.2.11.3. SWOT Analysis
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 2: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 3: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2019-2032
  • Table 4: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2019-2032
  • Table 5: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 6: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 7: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 8: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 9: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2019-2032
  • Table 10: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2019-2032
  • Table 11: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 12: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 13: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 14: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 15: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2019-2032
  • Table 16: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2019-2032
  • Table 17: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 18: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 19: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 20: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 21: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2019-2032
  • Table 22: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2019-2032
  • Table 23: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 24: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 25: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 26: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 27: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2019-2032
  • Table 28: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2019-2032
  • Table 29: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 30: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 31: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 32: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 33: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2019-2032
  • Table 34: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2019-2032
  • Table 35: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 36: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Prostate Cancer Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2024 & 2032
  • Figure 3: Global Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2024 & 2032
  • Figure 4: Global Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2024 & 2032
  • Figure 5: Global Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2024 & 2032
  • Figure 6: Global Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 7: Global Prostate Cancer Therapeutics Market Value (USD billion), by Region, 2024 & 2032
  • Figure 8: North America Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2024 & 2032
  • Figure 9: North America Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2024
  • Figure 10: North America Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 11: North America Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2024
  • Figure 12: North America Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2024 & 2032
  • Figure 13: North America Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2024
  • Figure 14: North America Prostate Cancer Therapeutics Market Value (USD billion), by Disease State, 2024 & 2032
  • Figure 15: North America Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2024
  • Figure 16: North America Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 17: North America Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2024
  • Figure 18: North America Prostate Cancer Therapeutics Market Value (USD billion), By Country, 2024 & 2032
  • Figure 19: North America Prostate Cancer Therapeutics Market Value Share (%), By Country, 2024
  • Figure 20: Europe Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2024 & 2032
  • Figure 21: Europe Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2024
  • Figure 22: Europe Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 23: Europe Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2024
  • Figure 24: Europe Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2024 & 2032
  • Figure 25: Europe Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2024
  • Figure 26: Europe Prostate Cancer Therapeutics Market Value (USD billion), by Disease State, 2024 & 2032
  • Figure 27: Europe Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2024
  • Figure 28: Europe Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 29: Europe Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2024
  • Figure 30: Europe Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 31: Europe Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 32: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2024 & 2032
  • Figure 33: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2024
  • Figure 34: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 35: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2024
  • Figure 36: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion),by Therapy, 2024 & 2032
  • Figure 37: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2024
  • Figure 38: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion), by Disease State, 2024 & 2032
  • Figure 39: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2024
  • Figure 40: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 41: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2024
  • Figure 42: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 43: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 44: Latin America Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2024 & 2032
  • Figure 45: Latin America Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2024
  • Figure 46: Latin America Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 47: Latin America Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2024
  • Figure 48: Latin America Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2024 & 2032
  • Figure 49: Latin America Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2024
  • Figure 50: Latin America Prostate Cancer Therapeutics Market Value (USD billion), by Disease State, 2024 & 2032
  • Figure 51: Latin America Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2024
  • Figure 52: Latin America Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 53: Latin America Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2024
  • Figure 54: Latin America Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 55: Latin America Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 56: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2024 & 2032
  • Figure 57: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2024
  • Figure 58: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 59: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2024
  • Figure 60: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2024 & 2032
  • Figure 61: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2024
  • Figure 62: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), by Disease State, 2024 & 2032
  • Figure 63: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2024
  • Figure 64: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 65: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2024
  • Figure 66: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 67: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 68: Global Prostate Cancer Therapeutics Market Share (%), By Company, 2024